Últimas noticias sobre Alvotech (NASDAQ:ALVO) Bolsa

Alvotech

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BBGI

BCAX

ELTX

FOXO

ISPC

JBHT

LYTS

MDXG

NATR

NUKK

OFIX

TMCI

TXNM

VIAV

WILC

Explora los mayores ganadores y perdedores en las operaciones previas al mercado. Descubre qué impulsó estos movimientos destacados.

Las acciones de Versus Systems (VS) aumentan un 71%; 20 acciones que se mueven en el premercado de EE.UU.

ALVOPETRO ENEGY LTD by Alvopetro Energy Ltd

Alvopetro Energy Ltd

ALVO MINERALS LTD by ALVO MINERALS LTD.

Piper Sandler analyst Nathan Race maintains First Business Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIZ#NASDAQ">FBIZ</a>) with a Overweight and raises the price target from $57 to $58.

Price Target

Analyst Ratings

FBIZ

Piper Sandler Maintains Overweight on First Business Finl Servs, Raises Price Target to $58

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 200 points on Monday.
The Dow traded down 0.27% to 40,004.11 while the NASDAQ fell 1.19% to 17,175.43. The S&amp;P 500 also fell, dropping, 0.72% to 5,485.36.
Check This Out: <a href="https://www.benzinga.com/25/04/45035424/top-3-health-care-stocks-that-may-rocket-higher-in-april">Top 3 Health Care Stocks That May Rocket Higher In April</a>
Leading and Lagging Sectors Financial shares jumped by 0.6% on Monday.
In trading on Monday, information technology fell by 0.6%.
Top Headline
Roper Technologies, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) reported better-than-expected earnings for its first quarter and raised its forecast.
The company posted first-quarter adjusted earnings per share of $4.78, beating the street view of $4.74. Quarterly sales of $1.88 billion outpaced the analyst consensus estimate of $1.82 billion.
Roper Technologies expects fiscal 2025 adjusted earnings per share of $19.80-$20.05 (compared to a previous outlook of $19.75-$20.00), versus the $19.92 estimate. It increased its full-year total revenue growth outlook to ~12% or $7.88 billion (compared to a previous outlook of 10%+ or $7.74 billion) and an analyst estimate of $7.74 billion. It reiterated organic revenue growth of +6-7%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) shares shot up 46% to $2.2999. Galmed signed a term sheet for the development of novel semaglutide sublingual formulation.</li>
<li>Shares of CG Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>)got a boost, surging 31% to $29.21 after the company announced that cretostimogene grenadenorepvec monotherapy data was presented at the American Urological Association Annual Meeting.</li>
<li>Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares were also up, gaining 42% to $1.15 after the company signed a secured credit facility with Yorkville Advisors. The company also reported preliminary first-quarter results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Spruce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares dropped 28% to $0.0935 after the company announced it approved a plan to implement a workforce reduction.</li>
<li>Shares of Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) were down 15% to $16.86.</li>
<li>Protara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) was down, falling 19% to $3.4899 as the company announced interim results highlighting durable clinical responses with TARA-002 In high-risk NMIBC.</li>
</ul>
Commodities In commodity news, oil traded down 2% to $61.78 while gold traded up 0.6% at $3,316.80.
Silver traded down 0.5% to $32.845 on Monday, while copper rose 0.1% to $4.90.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.74%, Germany's DAX 40 gained 0.67% and France's CAC 40 gained 0.87%. Spain's IBEX 35 Index gained 0.81%, while London's FTSE 100 rose 0.30%.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 surging 0.38%, China's Shanghai Composite falling 0.20%, Hong Kong's Hang Seng Index falling 0.04% and India's BSE Sensex gaining 1.27%.
Economics
The Dallas Fed manufacturing index will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45037469/stride-to-rally-around-10-here-are-10-top-analyst-forecasts-for-monday">Stride To Rally Around 10%? Here Are 10 Top Analyst Forecasts For</a> Monday.</li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

CGON

GLMD

GRPN

PLUG

SPRB

TARA

Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook

Piper Sandler analyst Justin Crowley maintains Eagle Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGBN#NASDAQ">EGBN</a>) with a Neutral and lowers the price target from $25 to $21.

EGBN

Piper Sandler Maintains Neutral on Eagle Bancorp, Lowers Price Target to $21

Piper Sandler analyst Matthew Clark maintains CVB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVBF#NASDAQ">CVBF</a>) with a Overweight and lowers the price target from $25 to $24.

CVBF

Piper Sandler Maintains Overweight on CVB Financial, Lowers Price Target to $24

Piper Sandler analyst Matthew Clark maintains Columbia Banking System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) with a Overweight and lowers the price target from $32 to $30.

COLB

Piper Sandler Maintains Overweight on Columbia Banking System, Lowers Price Target to $30

WIIM

Protara Therapeutics shares are trading lower. The company announced updated results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002

Citigroup analyst Paul Lejuez maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Neutral and lowers the price target from $330 to $275.

LULU

Citigroup Maintains Neutral on Lululemon Athletica, Lowers Price Target to $275

Piper Sandler analyst Justin Crowley maintains Civista Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIVB#NASDAQ">CIVB</a>) with a Neutral and raises the price target from $23 to $24.

CIVB

Piper Sandler Maintains Neutral on Civista Bancshares, Raises Price Target to $24

Citigroup analyst Paul Lejuez maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Buy and lowers the price target from $215 to $150.

DECK

Citigroup Maintains Buy on Deckers Outdoor, Lowers Price Target to $150

Piper Sandler analyst Thomas Champion maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Overweight and lowers the price target from $90 to $80.

Piper Sandler Maintains Overweight on Zillow Gr, Lowers Price Target to $80

Piper Sandler analyst Thomas Champion maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Neutral and lowers the price target from $5120 to $5077.

BKNG

Piper Sandler Maintains Neutral on Booking Holdings, Lowers Price Target to $5077

ONON

On Holding shares are trading higher after Citigroup upgraded the stock from Neutral to Buy, while cutting its price target from $65 to $60.

Citigroup analyst Paul Lejuez maintains Amer Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) with a Buy and lowers the price target from $36 to $30.

Citigroup Maintains Buy on Amer Sports, Lowers Price Target to $30

Piper Sandler analyst Thomas Champion maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and lowers the price target from $210 to $174.

EXPE

Piper Sandler Maintains Neutral on Expedia Group, Lowers Price Target to $174

Live On CNBC, Steve Weiss Announces Bought More UnitedHealth Group

Citigroup analyst Alicia Yap maintains JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) with a Buy and lowers the price target from $56 to $51.

Citigroup Maintains Buy on JD.com, Lowers Price Target to $51

Piper Sandler analyst Thomas Champion maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Neutral and lowers the price target from $145 to $132.

ABNB

Piper Sandler Maintains Neutral on Airbnb, Lowers Price Target to $132

Piper Sandler analyst Crispin Love upgrades Rithm Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RITM#NYSE">RITM</a>) from Neutral to Overweight and raises the price target from $12.5 to $14.

Upgrades

RITM

Piper Sandler Upgrades Rithm Capital to Overweight, Raises Price Target to $14

Piper Sandler analyst Paul Newsome upgrades Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) from Neutral to Overweight and lowers the price target from $384 to $378.

Piper Sandler Upgrades Aon to Overweight, Lowers Price Target to $378

Citigroup analyst Michael Rollins maintains Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) with a Buy and raises the price target from $425 to $445.

CHTR

Citigroup Maintains Buy on Charter Communications, Raises Price Target to $445

Health Care

Legal

Press Releases

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

General

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

Alvotech and Dr. Reddy's Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Comments

Alvotech

Noticias

Últimas noticias sobre Alvotech (NASDAQ:ALVO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL